Morphocell Technologies Secures Additional $10M in Series A Financing to Drive Liver Disease Therapies

Morphocell Technologies finalizes its Series A financing, adding US$10 million to reach a total of US$60 million, led by Investissement Québec and CDP Venture Capital. The additional funding marks a crucial step for Morphocell's endeavors in treating liver disease and establishing its first European subsidiary in Italy.